As of May 27
| -0.0001 / -0.01%|
The 2 analysts offering 12-month price forecasts for Transition Therapeutics Inc have a median target of 1.54, with a high estimate of 2.18 and a low estimate of 0.90. The median estimate represents a +92.11% increase from the last price of 0.80.
The current consensus among 3 polled investment analysts is to Hold stock in Transition Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.